Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer

Oncology Reports
Lingling Hu, Lanxiang Cong

Abstract

Fibroblast growth factor receptor 4 (FGFR4) has been confirmed to be associated with the progression and prognosis of ovarian cancer, while the underlying mechanism has not been well elucidated and the clinical significance of its ligand, fibroblast growth factor 19 (FGF19), has not been explored. To study the clinical significance of FGF19 in advanced‑stage serous ovarian cancer, we detected the expression of FGF19 and FGFR4 by immunohistochemistry (IHC), evaluated the correlation between FGF19 and clinicopathological factors by Chi-square (χ2) test, and analyzed the association between FGF19, FGFR4 and the overall survival rate using the Kaplan‑Meier method. As a result, we demonstrated that high expression of FGF19 and FGFR4 both predicted unfavorable prognosis (P=0.033 and 0.018, respectively), whereas FGF19-FGFR4 double high expression was a more sensitive prognostic factor of advanced-stage serous ovarian cancer (P<0.001). With experiments in vitro, we demonstrated that both recombinant FGF19 and secreted FGF19 promoted ovarian cancer proliferation and invasion by activating FGFR4 and the subsequent AKT-MAPK signaling pathway, suggesting that FGF19-FGFR4 signaling may auto-activate in a paracrine or autocrine manner. In c...Continue Reading

References

May 28, 1993·International Journal of Cancer. Journal International Du Cancer·S JaakkolaH Nevanlinna
Jan 30, 2002·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael Thun
May 3, 2005·Cytokine & Growth Factor Reviews·V P EswarakumarJ Schlessinger
Apr 7, 2006·The Journal of Biological Chemistry·Xiuqin ZhangDavid M Ornitz
Jul 9, 2008·Scandinavian Journal of Clinical and Laboratory Investigation·D StejskalP Stejskal
Dec 17, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kwang-Hoon SongJohn Y L Chiang
Jan 23, 2010·Nature Reviews. Cancer·Nicholas Turner, Richard Grose
Jan 13, 2012·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Feb 4, 2012·Genes & Development·Matthew J PotthoffDavid J Mangelsdorf
Mar 8, 2012·Advances in Experimental Medicine and Biology·Stacey A Jones
Jun 21, 2012·Gynecologic Oncology·Joanne KotsopoulosSteven A Narod
Dec 12, 2012·PloS One·Roberta Lelis DutraAdriana Madeira Álvares da Silva
Jan 25, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tarrik M ZaidSamuel C Mok
Feb 14, 2013·Endocrine-related Cancer·Catherine M OlsenUNKNOWN Ovarian Cancer Association Consortium
Feb 27, 2013·Cancer Research·Shu FengMichael Ittmann
May 23, 2013·Medicinal Research Reviews·Masaru Katoh, Hitoshi Nakagama
Sep 28, 2013·Critical Reviews in Oncology/hematology·Pierre-Emmanuel ColomboIsabelle Ray-Coquard
Jan 15, 2014·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Chen-Sheng LiZhen-Hai Zhang
Feb 26, 2014·Biochemical and Biophysical Research Communications·Yun-Fei XuYu-Xin Chen
May 17, 2014·Journal of Ovarian Research·Hyo Sook BaeJae Yun Song
Sep 16, 2014·Gynecologic Oncology·Monjri M ShahCharles A Leath
Oct 23, 2014·Journal of the National Cancer Institute·Cynthia A ThomsonMelinda L Irwin

❮ Previous
Next ❯

Citations

Dec 23, 2017·Reproduction : the Official Journal of the Society for the Study of Fertility·Anthony Estienne, Christopher A Price
Oct 17, 2018·Future Medicinal Chemistry·Nestor Prieto-DominguezYong Teng
Feb 7, 2018·Scientific Reports·Álvaro Quintanal-VillalongaLuis Paz-Ares
Aug 21, 2018·Endocrine Reviews·Emmanuel Somm, François R Jornayvaz
Mar 21, 2018·Current Cancer Drug Targets·Liwei LangYong Teng
May 8, 2018·Oncotarget·Shunta HoriKiyohide Fujimoto
May 18, 2020·Cellular Oncology (Dordrecht)·Meysam YousefiAlireza Pasdar

❮ Previous
Next ❯

Related Concepts